EBV-miR-BHRF1-2 targets PRDM1/Blimp1: Potential role in EBV lymphomagenesis

Leukemia

Volumn 30, Issue 3, 2016, Pages 594-604

  Ma, J ^a   Nie, K ^a   Redmond, D ^a   Liu, Y ^a   Elemento, O ^a   Knowles, D M ^a   Tam, W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; EPSTEIN BARR VIRUS MICRORNA BHRF1-2; MESSENGER RNA; MICRORNA; SCARNA20 PROTEIN; SMALL INTERFERING RNA; SMALL NUCLEOLAR RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; VIRUS PROTEIN; 3' UNTRANSLATED REGION; BHRF1 PROTEIN, HUMAN HERPESVIRUS 4; ISOPROTEIN; PARAFFIN; PRDM1 PROTEIN, HUMAN; REPRESSOR PROTEIN; VIRAL PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; B CELL LYMPHOMA; BINDING SITE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS LYMPHOMAGENESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DIFFUSE LARGE B CELL LYMPHOMA; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE FIXATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CARCINOGENESIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICRORNAS; MOLECULAR SEQUENCE DATA; PARAFFIN EMBEDDING; PROTEIN ISOFORMS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; RNA, SMALL NUCLEOLAR; SIGNAL TRANSDUCTION; TISSUE FIXATION; VIRAL PROTEINS;

EID: 84959345626     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.285     Document Type: Article

References (48)

1. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008; 26: 133-169
2. Boi M, Zucca E, Inghirami G, Bertoni F. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. Leuk Lymphoma 2014; 7: 1-6
3. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B-cell lymphoma. J Exp Med 2006; 203: 311-317
4. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090-4100
5. Kucuk C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA 2011; 108: 20119-20124
6. Zhang T, Ma J, Nie K, Yan J, Liu Y, Bacchi CE, et al. Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma. Blood Cancer J 2014; 4: e261
7. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010; 207: 751-762
8. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009; 325: 1006-1010
9. Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH, et al. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 2008; 173: 242-252
10. Nie K, Zhang T, Allawi H, Gomez M, Liu Y, Chadburn A, et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol 2010; 177: 1470-1479
11. Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y, et al. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res 2014; 33: 7
12. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006; 2: e23
13. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science 2004; 304: 734-736
14. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, Middeldorp J, et al A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 2011; 7: e1002193
15. Klinke O, Feederle R, Delecluse HJ. Genetics of Epstein-Barr virus microRNAs. Semin Cancer Biol 2014; 26: 52-59
16. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 2009; 386: 387-397
17. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virusencoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205: 2551-2560
18. Marquitz AR, Mathur A, Nam CS, Raab-Traub N. The Epstein-Barr Virus BART microRNAs target the pro-Apoptotic protein Bim. Virology 2011; 412: 392-400
19. Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, et al A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 2011; 7: e1001294
20. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 2010; 6: e1001063
21. Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, et al. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 2014; 33: 1258-1264
22. Dolken L, Malterer G, Erhard F, Kothe S, Friedel CC, Suffert G, et al. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 2010; 7: 324-334
23. Hollander N, Selvaraj P, Springer TA. Biosynthesis and function of LFA-3 in human mutant cells deficient in phosphatidylinositol-Anchored proteins. J Immunol 1988; 141: 4283-4290
24. Canene-Adams K. Preparation of formalin-fixed paraffin-embedded tissue for immunohistochemistry. Methods Enzymol 2013; 533: 225-233
25. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562-578
26. Sie L, Loong S, Tan EK. Utility of lymphoblastoid cell lines. J Neurosci Res 2009; 87: 1953-1959
27. Salamon D, Adori M, Ujvari D, Wu L, Kis LL, Madapura HS, et al. Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells. J Virol 2012; 86: 4701-4707
28. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013; 122: 328-340
29. Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia 2012; 26: 2343-2352
30. Luftig M, Yasui T, Soni V, Kang MS, Jacobson N, Cahir-McFarland E, et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA 2004; 101: 141-146
31. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001; 11: 435-444
32. Sugano N, Chen W, Roberts ML, Cooper NR. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J ExpMed 1997; 186: 731-737
33. Capello D, Cerri M, Muti G, Berra E, Oreste P, Deambrogi C, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003; 102: 3775-3785
34. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012; 25: 968-982
35. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874
36. Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBVnegative Burkitt lymphomas. Blood 2005; 106: 1031-1036
37. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, et al. Downregulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-Associated B-cell lymphomas. Blood 2011; 117: 5907-5917
38. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5: 396-400
39. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62
40. Giorgetti L, Siggers T, Tiana G, Caprara G, Notarbartolo S, Corona T, et al. Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. Mol Cell 2010; 37: 418-428
41. Schattner P, Barberan-Soler S, Lowe TM A computational screen for mammalian pseudouridylation guide H/ACA RNAs. RNA 2006; 12: 15-25
42. Bachellerie JP, Cavaille J, Huttenhofer A. The expanding snoRNA world. Biochimie 2002; 84: 775-790
43. Turunen JJ, Niemela EH, Verma B, Frilander MJ. The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev RNA 2013; 4: 61-76
44. Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, et al. Aberrant splicing of U12-Type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun 2015; 6: 6042
45. Caffarelli E, Fatica A, Prislei S, De Gregorio E, Fragapane P, Bozzoni I. Processing of the intron-encoded U16 and U18 snoRNAs: the conserved C and D boxes control both the processing reaction and the stability of the mature snoRNA. EMBO J 1996; 15: 1121-1131
46. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer?. Nat Rev Cancer 2012; 12: 84-88
47. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog 2012; 8: e1002484
48. Tam W, Gomez M, Nie K. Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas. Blood 2008; 111: 2488-2489; author reply 2489-2490